Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases
Genes · 19.01.2024 · 15 (1) · 123
DOI: 10.3390/genes15010123 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 19.01.2024. Verfasst von Luis Alberto Bravo-Vázquez und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Engineering and Sciences, Tecnologico de Monterrey, Campus Queretaro, Av. Epigmenio Gonzalez, No. 500 Fracc. San Pablo, Queretaro 76130, Me…. Hauptthemen laut MEDLINE: MicroRNAs, RNA, Long Noncoding, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are two crucial classes of transcripts that belong to the major group of non-coding RNAs (ncRNAs). These RNA molecules have significant influence over diverse molecular processes due to their crucial role as regulators of gene expression. However, the dysregulated expression of these ncRNAs constitutes a fundamental factor in the etiology and progression of a wide variety of multifaceted human diseases, including kidney diseases. In this context, over the past years, compelling evidence has shown that miRNAs and lncRNAs could be prospective targets for the development of next-generation drugs against kidney diseases as they participate in a number of disease-associated processes, such as podocyte and nephron death, renal fibrosis, inflammation, transition from acute kidney injury to chronic kidney disease, renal vascular changes, sepsis, pyroptosis, and apoptosis. Hence, in this current review, we critically analyze the recent findings concerning the therapeutic inferences of miRNAs and lncRNAs in the pathophysiological context of kidney diseases. Additionally, with the aim of driving advances in the formulation of ncRNA-based drugs tailored for the management of kidney diseases, we discuss some of the key challenges and future prospects that should be addressed in forthcoming investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Engineering and Sciences, Tecnologico de Monterrey, Campus Queretaro, Av. Epigmenio Gonzalez, No. 500 Fracc. San Pablo, Queretaro 76130, Mexico.
- Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Department of Medical Biotechnology, Faculty of Allied Health Sciences, Chennai 603103, India.
- Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, N-0316 Oslo, Norway.
ORCID-Profile: Luis Alberto Bravo-Vázquez, Sujay Paul, Luis David Márquez-Gallardo, Surajit Pathak, Asim K Duttaroy
Zitieren
APA
Bravo-Vázquez, L. A., Paul, S., Colín-Jurado, M. G., Márquez-Gallardo, L. D., Castañón-Cortés, L. G., Banerjee, A., Pathak, S., & Duttaroy, A. K. (2024). Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases. Genes, 15(1), 123. https://doi.org/10.3390/genes15010123
Vancouver
Bravo-Vázquez LA, Paul S, Colín-Jurado MG, Márquez-Gallardo LD, Castañón-Cortés LG, Banerjee A, et al. Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases. Genes. 2024;15(1):123. doi:10.3390/genes15010123
BibTeX
@article{BravoVzquez2024,
author = {Bravo-Vázquez, Luis Alberto and Paul, Sujay and Colín-Jurado, Miriam Guadalupe and Márquez-Gallardo, Luis David and Castañón-Cortés, Luis Germán and Banerjee, Antara and Pathak, Surajit and Duttaroy, Asim K},
title = {Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases},
journal = {Genes},
year = {2024},
volume = {15},
number = {1},
pages = {123},
doi = {10.3390/genes15010123}
}
EUVIMED